202
Participants
Start Date
January 11, 2022
Primary Completion Date
September 29, 2023
Study Completion Date
September 29, 2023
MT-1186
Oral edaravone
Placebo
Oral
Chefarzt Muskelzentrum/ALS Clinic Kantonsspital St.Gallen Muskelzentrum/ALS Clinic, Sankt Gallen
University Of Pittsburgh Medical Center, Pittsburgh
Johns Hopkins University, Baltimore
Neurology Associates, P.C - Lincoln, Lincoln
Woodland Research Northwest, LLC, Rogers
Nerve And Muscle Center Of Texas, Houston
Universitaetsklinikum Wuerzburg, Würzburg
University of Washington Medical Center, Seattle
UF Health Cancer Center/Clinical Trials Office, Gainesville
Emory University - School of Medicine, Atlanta
Northwestern University Feinberg School of Medicine, Chicago
West Virginia University School of Medicine (WVUSoM) - Movement Disorder Clinic, Morgantown
University of Alberta - Walter C Mackenzie Health Sciences Centre (WCM), Edmonton
Health Science Center Mcmaster University, Hamilton
London Health Sciences Centre - University Hospital, London
CHU de Quebec-Hopital-Enfant-Jesus, Québec
National Hospital Organization Higashinagoya National Hospital, Nagoya
Nagoya University Hospital, Nagoya
National Hospital Organization Chibahigashi National Hospital, Chiba
Murakami Karindoh Hospital, Fukuoka
Fukushima Medical University Hospital, Fukushima
Hiroshima University Hospital, Hiroshima
National Hospital Organization Iou National Hospital, Kanazawa
Kagawa University Hospital, Kita-gun
Yokohama City University Hospital, Yokohama
National Hospital Organization Kumamoto Saishun Medical Center, Kōshi
National Hospital Organization Utano National Hospital, Kyoto
Tohoku University Hospital, Sendai
Niigata University Medical & Dental Hospital, Niigata
Kansai Electric Power Hospital, Osaka
National Hospital Organization Osaka Toneyama Medical Center, Toyonaka
National Hospital Organization Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka
Tokyo Metropolitan Neurological Hospital, Fuchū
Teikyo University Hospital, Itabashi-ku
Toho University Omori Medical Center, Ōta-ku
Saitama Neuropsychiatric Institute, Saitama
Hanyang University Medical Center, Wangsimni-ro
Lead Sponsor
Mitsubishi Tanabe Pharma America Inc.
INDUSTRY